MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease

BACKGROUND: Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activated receptor gamma (PPARγ) modulator in vitro. Pharmacokinetic studies in mice sh...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Alzheimers Res Ther
Päätekijät: Pohland, Maximilian, Pellowska, Maren, Asseburg, Heike, Hagl, Stephanie, Reutzel, Martina, Joppe, Aljoscha, Berressem, Dirk, Eckert, Schamim H., Wurglics, Mario, Schubert‐Zsilavecz, Manfred, Eckert, Gunter P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809956/
https://ncbi.nlm.nih.gov/pubmed/29433569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-018-0342-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia